AstraZeneca and Neurimmune sign deal for NI006
07 January 2022 07:00 GMT AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006 Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition Alexion, AstraZeneca's Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid